نبذة مختصرة : Rabies is a lethal infectious disease that kills more than 55 thousand persons per year worldwide although death can be avoided if a post-exposure prophylaxis based in anti-rabies vaccine and immune globulins can be applied on time. After the onset of clinical signs, there is no effective therapy available. Cytokines and chemokines are crucial for host immune response development. This study had as purpose to evaluate the gene expression of cytokines and chemokynes related to the immune response and also to evaluate the efficacy of siRNAs therapy in mice inoculated with dog or bat virus. Results demonstrated that the gene expression profile was intrinsic to virus variant and the precocious production seemed to be more important than their expression levels for rabies survival. Therapy with siRNAs therapy showed no difference in the lethality rate between treated groups and controls but clinical evaluation of animals inoculated with dog variant showed less severity of clinical disease in the treated group compared with control, also associated with a low expression of N gene and of all immune markers evaluated at 5 days. Results provided some evidence of the efficacy of siRNAs therapy in infections due to dog variant but not due to bat variant in the present study ; A raiva é uma doença infecciosa letal que mata mais de 55 mil pessoas por ano em todo o mundo, embora a morte possa ser evitada se um tratamento pósexpositivo baseado no uso de vacina anti-rábica e imunoglobulinas for aplicado a tempo. Após o aparecimento dos sinais clínicos, não existe qualquer terapia eficaz disponível. As citocinas e quimiocinas são cruciais no desenvolvimento da resposta imune do hospedeiro. Este estudo teve como objetivo avaliar a expressão gênica de citocinas e quimiocinas relacionadas à resposta imune e também avaliar a eficácia da terapia com siRNAs em camundongos inoculados com virus de cão ou de morcego. Os resultados demonstraram que o perfil de expressão de citocinas e quimiocinas foi intrínseco `a variante viral e a ...
No Comments.